Zoetis (NYSE:ZTS) Releases FY 2026 Earnings Guidance

Zoetis (NYSE:ZTS) updated its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 6.150-6.250 for the period, compared to the consensus estimate of 6.870. The company issued revenue guidance of $9.1 billion-$9.3 billion, compared to the consensus revenue estimate of $9.8 billion.

Zoetis Stock Up 3.9%

Shares of ZTS traded up $2.91 on Thursday, reaching $77.30. The company’s stock had a trading volume of 17,748,529 shares, compared to its average volume of 5,841,110. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The firm has a fifty day moving average of $76.76 and a 200-day moving average of $100.95. Zoetis has a twelve month low of $71.47 and a twelve month high of $160.48. The stock has a market capitalization of $32.41 billion, a PE ratio of 11.50, a PEG ratio of 1.16 and a beta of 0.74.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s revenue was down .2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts predict that Zoetis will post 6.87 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ZTS. Barclays reduced their target price on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. TD Cowen reduced their price target on Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Weiss Ratings lowered shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Stifel Nicolaus cut their price target on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research note on Friday, June 26th. Finally, William Blair reissued a “market perform” rating on shares of Zoetis in a research note on Thursday. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $118.33.

Insider Transactions at Zoetis

In other news, Director Michael B. Mccallister acquired 3,000 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the purchase, the director owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This represents a 13.94% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Frank A. Damelio acquired 6,650 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders acquired 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by company insiders.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, topping consensus estimates of $1.84–$1.85 and rising from $1.76 a year earlier. The earnings beat likely helped support the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: Management said adjusted earnings increased despite a challenging demand environment, while Zoetis continues to benefit from its animal-health portfolio and strong profitability. Zoetis Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and finance leader, with reports also describing him as the incoming chief financial officer and chief operating officer. The leadership change may improve operational focus, but its financial impact is not yet clear. Zoetis Appoints Jay Saccaro
• Neutral Sentiment: William Blair reaffirmed its Market Perform rating, indicating that the firm sees a balanced risk-reward profile following the earnings release. William Blair Rating
• Negative Sentiment: The quarter’s revenue was $2.47 billion, below the $2.50 billion consensus estimate and essentially flat year over year. Softer U.S. pet-care demand, fewer veterinary visits and increased price sensitivity remain key headwinds. Zoetis Q2 Earnings and Outlook
• Negative Sentiment: Zoetis cut its fiscal 2026 outlook to adjusted EPS of $6.15–$6.25 and revenue of $9.1–$9.3 billion, well below consensus expectations of approximately $6.87 EPS and $9.8 billion in revenue. This guidance reduction limits the positive impact of the quarterly earnings beat.

Institutional Investors Weigh In On Zoetis

Several institutional investors and hedge funds have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. grew its holdings in shares of Zoetis by 3,311.3% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 158,250 shares of the company’s stock worth $19,912,000 after purchasing an additional 153,611 shares in the last quarter. Strive Financial Group LLC bought a new position in shares of Zoetis during the 4th quarter worth approximately $390,000. Beacon Pointe Advisors LLC grew its holdings in shares of Zoetis by 3.6% in the 4th quarter. Beacon Pointe Advisors LLC now owns 9,525 shares of the company’s stock worth $1,198,000 after purchasing an additional 327 shares during the last quarter. First Citizens Bank & Trust Co. raised its stake in shares of Zoetis by 34.8% in the fourth quarter. First Citizens Bank & Trust Co. now owns 58,495 shares of the company’s stock valued at $7,360,000 after acquiring an additional 15,115 shares during the last quarter. Finally, EP Wealth Advisors LLC bought a new stake in shares of Zoetis during the fourth quarter worth $35,365,000. 92.80% of the stock is owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.